First Trust Advisors LP lowered its holdings in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 5.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,990 shares of the medical research company’s stock after selling 5,409 shares during the quarter. First Trust Advisors LP owned 0.15% of PRA Health Sciences worth $7,235,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PRAH. Teachers Advisors LLC raised its position in shares of PRA Health Sciences by 2.6% during the first quarter. Teachers Advisors LLC now owns 251,007 shares of the medical research company’s stock worth $16,373,000 after purchasing an additional 6,402 shares during the period. Legal & General Group Plc raised its position in shares of PRA Health Sciences by 7.1% during the first quarter. Legal & General Group Plc now owns 9,943 shares of the medical research company’s stock worth $649,000 after purchasing an additional 663 shares during the period. Dimensional Fund Advisors LP raised its position in shares of PRA Health Sciences by 61.8% during the first quarter. Dimensional Fund Advisors LP now owns 295,974 shares of the medical research company’s stock worth $19,306,000 after purchasing an additional 113,074 shares during the period. BlackRock Inc. raised its position in shares of PRA Health Sciences by 43,947.8% during the first quarter. BlackRock Inc. now owns 2,857,381 shares of the medical research company’s stock worth $186,387,000 after purchasing an additional 2,850,894 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in shares of PRA Health Sciences by 56.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 212,627 shares of the medical research company’s stock worth $13,870,000 after purchasing an additional 77,057 shares during the period. 97.60% of the stock is currently owned by institutional investors.

PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at $79.60 on Tuesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market capitalization of $5,010.01, a P/E ratio of 29.07, a price-to-earnings-growth ratio of 1.37 and a beta of 0.43. PRA Health Sciences, Inc. has a one year low of $51.16 and a one year high of $84.38.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. The firm had revenue of $494.55 million during the quarter, compared to the consensus estimate of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The business’s revenue was up 23.7% compared to the same quarter last year. During the same period last year, the company earned $0.64 earnings per share. equities research analysts predict that PRA Health Sciences, Inc. will post 3.2 EPS for the current year.

TRADEMARK VIOLATION WARNING: “PRA Health Sciences, Inc. (PRAH) Shares Sold by First Trust Advisors LP” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/pra-health-sciences-inc-prah-shares-sold-by-first-trust-advisors-lp/1701912.html.

A number of research firms have recently commented on PRAH. KeyCorp reaffirmed a “buy” rating and set a $93.00 price target (up previously from $86.00) on shares of PRA Health Sciences in a research report on Monday, October 30th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $101.00 price objective on shares of PRA Health Sciences in a report on Friday, October 27th. Credit Suisse Group increased their price objective on PRA Health Sciences from $90.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, October 26th. Jefferies Group LLC reiterated a “buy” rating and set a $95.00 price objective on shares of PRA Health Sciences in a report on Thursday, October 26th. Finally, Robert W. Baird reiterated a “buy” rating and set a $88.00 price objective on shares of PRA Health Sciences in a report on Monday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. PRA Health Sciences has an average rating of “Buy” and a consensus target price of $88.09.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.